252 related articles for article (PubMed ID: 34683173)
1. Influence of Genetic Polymorphisms on Clinical Outcomes of Glatiramer Acetate in Multiple Sclerosis Patients.
Zarzuelo-Romero MJ; Pérez-Ramírez C; Cura Y; Carrasco-Campos MI; Marangoni-Iglecias LM; Ramírez-Tortosa MC; Jiménez-Morales A
J Pers Med; 2021 Oct; 11(10):. PubMed ID: 34683173
[TBL] [Abstract][Full Text] [Related]
2. Pharmacogenetics of glatiramer acetate therapy for multiple sclerosis: the impact of genome-wide association studies identified disease risk loci.
Kulakova O; Bashinskaya V; Kiselev I; Baulina N; Tsareva E; Nikolaev R; Kozin M; Shchur S; Favorov A; Boyko A; Favorova O
Pharmacogenomics; 2017 Nov; 18(17):1563-1574. PubMed ID: 29095108
[TBL] [Abstract][Full Text] [Related]
3. Pharmacogenetics of glatiramer acetate therapy for multiple sclerosis reveals drug-response markers.
Grossman I; Avidan N; Singer C; Goldstaub D; Hayardeny L; Eyal E; Ben-Asher E; Paperna T; Pe'er I; Lancet D; Beckmann JS; Miller A
Pharmacogenet Genomics; 2007 Aug; 17(8):657-66. PubMed ID: 17622942
[TBL] [Abstract][Full Text] [Related]
4. Drug adherence and multidisciplinary care in patients with multiple sclerosis: protocol of a prospective, web-based, patient-centred, nation-wide, Dutch cohort study in glatiramer acetate treated patients (CAIR study).
Jongen PJ; Hengstman G; Hupperts R; Schrijver H; Gilhuis J; Vliegen JH; Hoogervorst E; van Huizen M; van Munster E; Samijn J; de Schryver E; Siepman T; Tonk M; Zandbergen E; ten Holter J; van der Kruijk R; Borm G
BMC Neurol; 2011 Mar; 11():40. PubMed ID: 21450086
[TBL] [Abstract][Full Text] [Related]
5. A pharmacogenetic signature of high response to Copaxone in late-phase clinical-trial cohorts of multiple sclerosis.
Ross CJ; Towfic F; Shankar J; Laifenfeld D; Thoma M; Davis M; Weiner B; Kusko R; Zeskind B; Knappertz V; Grossman I; Hayden MR
Genome Med; 2017 May; 9(1):50. PubMed ID: 28569182
[TBL] [Abstract][Full Text] [Related]
6. Allelic combinations of immune-response genes associated with glatiramer acetate treatment response in Russian multiple sclerosis patients.
Tsareva EY; Kulakova OG; Boyko AN; Shchur SG; Lvovs D; Favorov AV; Gusev EI; Vandenbroeck K; Favorova OO
Pharmacogenomics; 2012 Jan; 13(1):43-53. PubMed ID: 22111603
[TBL] [Abstract][Full Text] [Related]
7. First-line disease-modifying therapies in paediatric multiple sclerosis: a comprehensive overview.
Johnston J; So TY
Drugs; 2012 Jun; 72(9):1195-211. PubMed ID: 22642799
[TBL] [Abstract][Full Text] [Related]
8. What is new in the treatment of multiple sclerosis?
Weinstock-Guttman B; Jacobs LD
Drugs; 2000 Mar; 59(3):401-10. PubMed ID: 10776827
[TBL] [Abstract][Full Text] [Related]
9. Pharmacogenomics of interferon beta and glatiramer acetate response: a review of the literature.
Mahurkar S; Suppiah V; O'Doherty C
Autoimmun Rev; 2014 Feb; 13(2):178-86. PubMed ID: 24189284
[TBL] [Abstract][Full Text] [Related]
10. Comparative pharmacogenetics of multiple sclerosis: IFN-β versus glatiramer acetate.
Kulakova OG; Tsareva EY; Lvovs D; Favorov AV; Boyko AN; Favorova OO
Pharmacogenomics; 2014 Apr; 15(5):679-85. PubMed ID: 24798724
[TBL] [Abstract][Full Text] [Related]
11. Impact of glatiramer acetate on paraclinical markers of neuroprotection in multiple sclerosis: A prospective observational clinical trial.
Ehling R; Di Pauli F; Lackner P; Rainer C; Kraus V; Hegen H; Lutterotti A; Kuenz B; De Zordo T; Schocke M; Glatzl S; Löscher WN; Deisenhammer F; Reindl M; Berger T
J Neuroimmunol; 2015 Oct; 287():98-105. PubMed ID: 26439969
[TBL] [Abstract][Full Text] [Related]
12. [Genetic Markers for Personalized Therapy of Polygenic Diseases: Pharmacogenetics of Multiple Sclerosis].
Tsareva EY; Favorova OO; Boyko AN; Kulakova OG
Mol Biol (Mosk); 2019; 53(4):574-599. PubMed ID: 31397433
[TBL] [Abstract][Full Text] [Related]
13. Effect of glatiramer acetate (Copaxone) on CD4+CD25high T regulatory cells and their IL-10 production in multiple sclerosis.
Putheti P; Soderstrom M; Link H; Huang YM
J Neuroimmunol; 2003 Nov; 144(1-2):125-31. PubMed ID: 14597106
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of glatiramer acetate compared to other multiple sclerosis therapies.
Izquierdo G; García-Agua Soler N; Rus M; García-Ruiz AJ
Brain Behav; 2015 Jun; 5(6):e00337. PubMed ID: 26085963
[TBL] [Abstract][Full Text] [Related]
15. Combination of Myelin Basic Protein Gene Polymorphisms with HLA-DRB1*1501 in Iranian Patients with Multiple Sclerosis.
Nejati P; Attar M; Rahimian M; Fathi D; Shahbazi M
Iran J Immunol; 2017 Sep; 14(3):231-239. PubMed ID: 28919586
[TBL] [Abstract][Full Text] [Related]
16. Glatiramer acetate therapy for multiple sclerosis: a review.
Perumal J; Filippi M; Ford C; Johnson K; Lisak R; Metz L; Tselis A; Tullman M; Khan O
Expert Opin Drug Metab Toxicol; 2006 Dec; 2(6):1019-29. PubMed ID: 17125414
[TBL] [Abstract][Full Text] [Related]
17. 12-months prospective Pentraxin-3 and metabolomic evaluation in multiple sclerosis patients treated with glatiramer acetate.
Signoriello E; Iardino P; Casertano S; De Lucia D; Pucciarelli A; Puoti G; Chiosi E; Lus G
J Neuroimmunol; 2020 Nov; 348():577385. PubMed ID: 32927398
[TBL] [Abstract][Full Text] [Related]
18. Glatiramer acetate: mechanisms of action in multiple sclerosis.
Schrempf W; Ziemssen T
Autoimmun Rev; 2007 Aug; 6(7):469-75. PubMed ID: 17643935
[TBL] [Abstract][Full Text] [Related]
19. Therapy with glatiramer acetate for multiple sclerosis.
Munari L; Lovati R; Boiko A
Cochrane Database Syst Rev; 2004; (1):CD004678. PubMed ID: 14974077
[TBL] [Abstract][Full Text] [Related]
20. HLA DR and DQ alleles and haplotypes associated with clinical response to glatiramer acetate in multiple sclerosis.
Dhib-Jalbut S; Valenzuela RM; Ito K; Kaufman M; Ann Picone M; Buyske S
Mult Scler Relat Disord; 2013 Oct; 2(4):340-8. PubMed ID: 25877844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
